Overview
Helicobacter pylori (H. pylori) is a kind of bacteria. It enters a person's body and lives in the digestive tract. H. pylori may cause sores, called ulcers, in your stomach or the small intestine. In rare cases, it can lead to stomach cancer.
H. pylori infection is widespread. About two-thirds of the total world population has it. For the majority, it doesn't cause ulcers or other symptoms.
Some treatments can kill bacteria and help heal sores if you face problems.
Voqueza is the latest treatment approved by FDA for H. pylori infection treatment.
Continue reading further to learn more about this new treatment!
What is this new H. pylori treatment?
On 3rd May 2022, the FDA approved Voquezna Dual Pak and Voquezna Triple Pak for Helicobacter pylori infection treatment in adults.
Voquezna Dual Pak and Voquezna Triple Pak are blends of different drugs. These include vonoprazan, oral potassium-competitive acid blockers (PCAB), and antibiotics. PCABs are top-tier medicines that stop acid secretion in the stomach.
Vonoprazan suppresses acids, which help achieve the pH levels required to enhance the effectiveness of antibiotics.
The doctor may choose Voquezna Dual Pak or Voquezna Triple Pak, depending on the severity of the case.
The treatment is usually administered for 14 days.
Does this new stomach infection treatment have any side effects?
Like any other treatment, this new H. pylori treatment has adverse effects. No matter how minimal, you should know them!
We have mentioned them below.
Please read them carefully!
Below are some of the known side effects of this new H. pylori infection treatment:
Voquezna Triple Pak | Voquezna Dual Pak |
|
|
Before considering this new pylori bacteria treatment, you should know about its safety and efficacy.
Hence, we present you with its clinical trial results.
Please pay attention!
Clinical Trial Results
Here is the clinical trial result, based on what FDA approved for this new stomach infection medication.
- 1046 patients were randomly given Voquezna Triple Pak and Voquezna Dual Pak daily. Each treatment regimen was administered for 14 days.
- Results showed that H. pylori eradication rates in the patients were 84.7% and 78.5% with Voquezna Triple and Dual Pak, respectively.
There are many more things you should know before considering a treatment.
Please read them carefully! We have discussed them below.
What Should You Know Before Considering this H. Pylori Treatment?
It would be best if you remember the following before opting for this new Helicobacter pylori treatment:
- Voquezna Triple Pak is not indicated for patients with known QT prolongation or taking drugs known to prolong the QT interval.
- Voquezna Triple Pak should be immediately discontinued if signs and symptoms of hepatitis occur.
- Voquezna Triple Pak is not indicated for pregnant women.
- Breastfeeding is not suggested during treatment, and a lactating woman may pump and reject breast milk for 2 days after Voquezna Triple Pak and Voquezna Dual Pak administration.
- Voquezna Triple Pak can significantly increase the risk of torsades de pointes.
- Voquezna Triple Pak is not indicated in patients with severe renal and moderate to severe hepatic impairment.
References:
https://www.webmd.com/digestive-disorders/default.htm
https://www.empr.com/home/news/
https://www.drugs.com/history/voquezna-triple-pak.html
